Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
Drug repositioning is an alternative strategy redirecting existing drugs for new disease. We have previously reported an antitumor effect of statins, antidyslipidemic drugs, on ovarian cancer in vitro and in vivo. In this study, we investigated the antitumor effects of other mevalonate pathway inhibitors and the mechanism of the antitumor effect from a metabolic perspective. The effects of inhibitors of the mevalonate pathway on tumor cell growth were evaluated in vitro. Bisphosphonates that inhibit this pathway are commonly used as antiosteoporotic drugs, and antitumor effects of the bisphosphonate were examined in vitro and in vivo. Metabolites in SKOV3 ovarian cancer cells were analyzed before and after lovastatin treatment, using capillary electrophoresis-mass spectrometry. All mevalonate pathway inhibitors showed concentration-dependent inhibitory effects on tumor cell growth. Particularly marked effects were obtained with inhibitors of farnesyltransferase and geranylgeranyltransferase. The bisphosphonate was also shown to have an antitumor effect in vivo. The expression of autophagy marker LC3A/3B was increased in cells after treatment. In metabolomics analysis, lovastatin treatment increased the metabolites involved in the tricarboxylic acid cycle while reducing the metabolites associated with glycolysis. Also it decreased glutathione and resulted to work with chemotherapeutic agents synergistically. Inhibition at any point in the mevalonate pathway, and especially of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, suppresses growth of ovarian cancer cells. Inhibition of this pathway may induce autophagy, cause a shift to activation of the tricarboxylic acid cycle and enhance susceptibility to chemotherapy. Drug repositioning targeting mevalonate pathway for ovarian cancer deserves consideration for clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 42 vom: 22. Sept., Seite 72147-72156 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kobayashi, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bisphosphonate |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.20046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277379520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277379520 | ||
| 003 | DE-627 | ||
| 005 | 20231225014059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.20046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0924.xml |
| 035 | |a (DE-627)NLM277379520 | ||
| 035 | |a (NLM)29069775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kobayashi, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Drug repositioning is an alternative strategy redirecting existing drugs for new disease. We have previously reported an antitumor effect of statins, antidyslipidemic drugs, on ovarian cancer in vitro and in vivo. In this study, we investigated the antitumor effects of other mevalonate pathway inhibitors and the mechanism of the antitumor effect from a metabolic perspective. The effects of inhibitors of the mevalonate pathway on tumor cell growth were evaluated in vitro. Bisphosphonates that inhibit this pathway are commonly used as antiosteoporotic drugs, and antitumor effects of the bisphosphonate were examined in vitro and in vivo. Metabolites in SKOV3 ovarian cancer cells were analyzed before and after lovastatin treatment, using capillary electrophoresis-mass spectrometry. All mevalonate pathway inhibitors showed concentration-dependent inhibitory effects on tumor cell growth. Particularly marked effects were obtained with inhibitors of farnesyltransferase and geranylgeranyltransferase. The bisphosphonate was also shown to have an antitumor effect in vivo. The expression of autophagy marker LC3A/3B was increased in cells after treatment. In metabolomics analysis, lovastatin treatment increased the metabolites involved in the tricarboxylic acid cycle while reducing the metabolites associated with glycolysis. Also it decreased glutathione and resulted to work with chemotherapeutic agents synergistically. Inhibition at any point in the mevalonate pathway, and especially of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, suppresses growth of ovarian cancer cells. Inhibition of this pathway may induce autophagy, cause a shift to activation of the tricarboxylic acid cycle and enhance susceptibility to chemotherapy. Drug repositioning targeting mevalonate pathway for ovarian cancer deserves consideration for clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bisphosphonate | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a mevalonate pathway | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a statin | |
| 700 | 1 | |a Kashima, Hiroyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmanto, Yohan Suryo |e verfasserin |4 aut | |
| 700 | 1 | |a Banno, Kouji |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Matoba, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Iijima, Moito |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Kunitomi, Haruko |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Masataka |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Kanako |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Masuda, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tominaga, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Daisuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 42 vom: 22. Sept., Seite 72147-72156 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:42 |g day:22 |g month:09 |g pages:72147-72156 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.20046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 42 |b 22 |c 09 |h 72147-72156 | ||